Royal Bank Of Canada upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a sector perform rating to an outperform rating in a report published on Monday morning. The brokerage currently has $83.00 price objective on the stock.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

SRPT has been the subject of several other research reports. JMP Securities reissued a sell rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Piper Jaffray Cos. raised shares of Sarepta Therapeutics from a neutral rating to an overweight rating in a research note on Monday. Cowen and Company reissued a hold rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Janney Montgomery Scott reissued a hold rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. Finally, William Blair raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $88.00 target price for the company in a research note on Monday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of Buy and a consensus target price of $48.70.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The stock’s 50 day moving average is $30.01 and its 200 day moving average is $21.91. The firm’s market cap is $2.92 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $61.60.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business earned ($0.87) EPS. On average, analysts anticipate that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In other news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the sale, the vice president now directly owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. BlackRock Fund Advisors increased its stake in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp increased its stake in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $302,000. National Planning Corp increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares in the last quarter. 72.09% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.